This is a first in human dose escalation trial to determine the safety of administering GPC2 CAR T cells in patients with advanced neuroblastoma or retinoblastoma.
Patients must be ≥ 1 year of age
Patients must have high-risk neuroblastoma according to COG risk classification at the time of study enrollment. Patients who were initially considered low- or intermediate-risk, but then reclassified as high-risk are also eligible.
That is recurrent/relapsed or refractory/persistent according to INRC AND
For which standard curative measures do not exist or are no longer effective.
Patients with active hepatitis B or active hepatitis C.
Patients with HIV infection.
Patients with uncontrolled active infection.
Patients with primary or acquired immunodeficiency disorder.
Stephan Grupp MD PhD
Lead sponsor
Children's Hospital of Philadelphia
Sponsor institution
Children's Hospital of Philadelphia
Collaborator
Gilead Sciences
Collaborator
University of Pennsylvania
Collaborator
National Cancer Institute (NCI)
Collaborator
Kite, A Gilead Company
Collaborator